Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03142165 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants
A Phase 1 study of Fibrosis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT03142165 is a Phase 1 study of Fibrosis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 33 participants, below the 218-participant average among 10 other Fibrosis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03142165, a Phase 1 study of Fibrosis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the safety and tolerability of BMS-986263 in healthy volunteers.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Diphenhydramine
- DRUG Famotidine
- DRUG BMS-986263
Study Locations (1)
California
- Wcct Global, Llc - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-05-11 |
| Est. Completion | 2017-11-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03142165
The ClinicalTrials.gov registry entry for NCT03142165 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 10 other Fibrosis trials with a reported enrollment target (85% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibrosis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03142165 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03142165 about?
NCT03142165 is a clinical study titled "A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants". The purpose of this study is to assess the safety and tolerability of BMS-986263 in healthy volunteers.
What is the current status of trial NCT03142165?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2017-05-11. Estimated completion is 2017-11-29.
What conditions does trial NCT03142165 study?
This clinical trial studies the following conditions: Fibrosis.
What interventions are being tested in trial NCT03142165?
The interventions under investigation include: Placebo (OTHER), Diphenhydramine (DRUG), Famotidine (DRUG), BMS-986263 (DRUG).
Who is sponsoring clinical trial NCT03142165?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03142165 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
RECRUITING · Phase 2
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
RECRUITING · Phase 2
-
Blood Collection Biorepository for Liver Disease Research
RECRUITING
-
A Study of Mosliciguat in PH-ILD
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.